Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: A cross-sectional study of women with benign breast disease

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Horne, Hisani N ^a,b   Sherman, Mark E ^a   Pfeiffer, Ruth M ^a   Figueroa, Jonine D ^c   Khodr, Zeina G ^a   Falk, Roni T ^a   Pollak, Michael ^d   Patel, Deesha A ^a,e   Palakal, Maya M ^a   Linville, Laura ^a   Papathomas, Daphne ^a   Geller, Berta ^f   Vacek, Pamela M ^f   Weaver, Donald L ^f   Chicoine, Rachael ^f   Shepherd, John ^g   Mahmoudzadeh, Amir Pasha ^g   Wang, Jeff ^g,h   Fan, Bo ^g   Malkov, Serghei ^g   Herschorn, Sally ^g   Hewitt, Stephen M ^a   Brinton, Louise A ^a   Gierach, Gretchen L ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACINAR CELL; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CELL; BREAST DENSITY; BREAST DISEASE; BREAST DUCT; CANCER RISK; CELL COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INVOLUTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; SOMATOMEDIN BINDING PROTEIN 3 BLOOD LEVEL; SOMATOMEDIN C BLOOD LEVEL; TERMINAL DUCT LOBULAR UNIT INVOLUTION; UNIVERSITY HOSPITAL; ABNORMALITIES; BLOOD; BREAST; BREAST TUMOR; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION; GENETICS; MAMMARY GLAND; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; BREAST; BREAST DENSITY; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; MIDDLE AGED; RISK FACTORS;

EID: 84958214235     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0678-4     Document Type: Article

References (51)

1. Ghosh K, Vachon CM, Pankratz VS, Vierkant RA, Anderson SS, Brandt KR, et al. Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst. 2010;102(22):1716-23.
2. Henson DE, Tarone RE. On the possible role of involution in the natural history of breast cancer. Cancer. 1993;71(6 Suppl):2154-6.
3. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst. 2006;98(22):1600-7.
4. McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, et al. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol. 2009;27(35):5893-8.
5. Baer HJ, Collins LC, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer. 2009;115(7):1404-11.
6. Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, et al. Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology. J Natl Cancer Inst 2014, 106(10).
7. Dearth RK, Delgado DA, Hiney JK, Pathiraja T, Oesterreich S, Medina D, et al. Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer. Cancer Prev Res (Phila). 2010;3(3):312-21.
8. Rowzee AM, Lazzarino DA, Rota L, Sun Z, Wood TL. IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia. 2008;13(4):361-70.
9. Su HY, Cheng WT. Increased milk yield in transgenic mice expressing insulin-like growth factor 1. Anim Biotechnol. 2004;15(1):9-19.
10. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530-42.
11. Muller C, Wallaschofski H, Brabant G, Wahnschaffe U, Samietz S, Nauck M, et al. The association between IGF-I/IGFBP-3 and subclinical end points: epidemiology faces the limits. J Clin Endocrinol Metab. 2014;99(8):2804-12.
12. Tsilidis KK, Papatheodorou SI, Evangelou E, Ioannidis JP. Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. J Natl Cancer Inst. 2012;104(24):1867-78.
13. Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, Pollak MN, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. Breast Cancer Res. 2012;14(2):R44.
14. Ghosh K, Hartmann LC, Reynolds C, Visscher DW, Brandt KR, Vierkant RA, et al. Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol. 2010;28(13):2207-12.
15. Ginsburg OM, Martin LJ, Boyd NF. Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer. 2008;99:1369-74.
16. Gierach GL, Patel DA, Pfeiffer RM, Figueroa JD, Linville L, Papathomas D, et al. Relationship of terminal duct lobular unit involution of the breast with area and volume mammographic densities. Cancer Prev Res (Phila). 2016; 9(2): 149-58.
17. Gierach GL, Geller BM, Shepherd JA, Patel DA, Vacek PM, Weaver DL, et al. Comparison of mammographic density assessed as volumes and areas among women undergoing diagnostic image-guided breast biopsy. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2338-48.
18. Malkov S, Wang J, Kerlikowske K, Cummings SR, Shepherd JA. Single x-ray absorptiometry method for the quantitative mammographic measure of fibroglandular tissue volume. Med Phys. 2009;36(12):5525-36.
19. Prevrhal S, Shepherd JA, Smith-Bindman R, Cummings SR, Kerlikowske K. Accuracy of mammographic breast density analysis: results of formal operator training. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1389-93.
20. Shepherd JA, Kerlikowske K, Ma L, Duewer F, Fan B, Wang J, et al. Volume of mammographic density and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1473-82.
21. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994;39(10):1629-38.
22. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, et al. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013;8(12):e81653.
23. Eng A, Gallant Z, Shepherd J, McCormack V, Li J, Dowsett M, et al. Digital mammographic density and breast cancer risk: a case control study of six alternative density assessment methods. Breast Cancer Res. 2014;16(5):439.
24. Breastscreening.cancer.gov. http://breastscreening.cancer.gov/.
25. Khodr ZG, Sherman ME, Pfeiffer RM, Gierach GL, Brinton LA, Falk RT, et al. Circulating sex hormones and terminal duct lobular unit involution of the normal breast. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2765-73.
26. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1065-73.
27. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol. 2009;19(12):841-9.
28. Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland A, Roswall N, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2012;106(5):1004-10.
29. dos Santos SI, Johnson N, De Stavola B, Torres-Mejia G, Fletcher O, Allen DS, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006;15(3):449-55.
30. Long JS. Count Outcomes: Regression Models for Counts. 1st ed. Thousand Oaks: SAGE Publications, Inc.; 1997.
31. R: A language environment for statistical computing. http://www.R-project.org/.
32. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 2000;275(24):18447-53.
33. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol. 1997;152(1):39-47.
34. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, Woitge HW, Blum WF, Wuster C, et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. J Clin Endocrinol Metab. 1996;81(7):2534-40.
35. Aimaretti G, Boschetti M, Corneli G, Gasco V, Valle D, Borsotti M, et al. Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest. 2008;31(5):445-9.
36. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res. 2000;60(14):3744-8.
37. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, et al. The association of breast mitogens with mammographic densities. Br J Cancer. 2002;87(8):876-82.
38. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Insulin-like growth factor and mammographic density in postmenopausal Norwegian women. Cancer Epidemiol Biomarkers Prev. 2007;16(1):57-62.
39. Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, et al. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat. 2008;108(1):57-67.
40. McCormack VA, Dowsett M, Folkerd E, Johnson N, Palles C, Coupland B, et al. Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res. 2009;11(3):R38.
41. Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Aiello Bowles EJ, et al. The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res Treat. 2012;131(1):255-65.
42. Martin LJ, Boyd NF. Mammographic density - potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res. 2008;10(1):201.
43. Neuenschwander S, Schwartz A, Wood TL, Roberts Jr CT, Hennighausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996;97(10):2225-32.
44. Vierkant RA, Hartmann LC, Pankratz VS, Anderson SS, Radisky D, Frost MH, et al. Lobular involution: localized phenomenon or field effect? Breast Cancer Res Treat. 2009;117(1):193-6.
45. Llanos AA, Brasky TM, Dumitrescu RG, Marian C, Makambi KH, Kallakury BV, et al. Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women. Breast Cancer Res Treat. 2013;138(2):571-9.
46. Lavigne JA, Wimbrow HH, Clevidence BA, Albert PS, Reichman ME, Campbell WS, et al. Effects of alcohol and menstrual cycle on insulin-like growth factor-I and insulin-like growth factor binding protein-3. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2264-7.
47. Hovhannisyan G, Chow L, Schlosser A, Yaffe MJ, Boyd NF, Martin LJ. Differences in measured mammographic density in the menstrual cycle. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1993-9.
48. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab. 2001;72(2):144-54.
49. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2147-53.
50. DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, et al. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer. 2003;88(2):277-82.
51. Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, et al. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine-Related cancer. 2010;17(1):51-60.